Startup Failures Uncovered · Episode 3 · 4 min · English audio · 4 May 2026
Theranos: The $9 Billion Lie—When Vision Crosses the Line Into Deception
A brutally honest post-mortem on Theranos' collapse, exposing fatal decisions and hard lessons for every founder.
From the show
Join us weekly as we dive deep into startup failures, revealing what went wrong, the critical decisions that led to their downfall, and candid insights from…
Tech & Startups · 25 episodes · Latest 26 October 2026 · English audio
Make a show like thisWith the Lissin app for iPhone
What this episode covers
A brutally honest post-mortem on Theranos' collapse, exposing fatal decisions and hard lessons for every founder.
Play this episode
4 min of audio, free in your browser — no account, no app.
Transcript
588 words · Script-based transcript; wording may differ from the recording.
In May 2016, Theranos voided every single blood test result from its Edison machines for all of 2014 and 2015. That’s tens of thousands of corrected reports sent to real doctors and real patients, admitting the data they were given was garbage. We keep talking about founders whose vision gets so big it breaks reality, but this... this is different. This wasn't just hubris. This was a nine billion dollar lie built on a box that did nothing. Elizabeth Holmes didn't just fail to execute. She chose to deceive, and that choice burned almost a billion dollars in capital and put actual lives at risk. So how did it get that bad? First, the technology was a complete fiction.
The pitch was revolutionary: a sleek little box called the Edison could run over two hundred tests from a single drop of blood. The reality? The Edison could barely run a dozen tests, and it failed those constantly. So what did Holmes and her COO, Sunny Balwani, do? They cheated. They bought off-the-shelf machines from Siemens—the exact old-school tech they claimed to be disrupting—and secretly ran most of the tests on them. They even had to dilute the tiny finger-prick samples with saline to get enough volume for the Siemens machines to work, which, if you know anything about lab science, is an absolute joke. It completely destroys the integrity of the result.
And who was supposed to be watching this? A board of directors, right? Theranos had a STACKED board. We're talking Henry Kissinger, George Shultz, James Mattis. Heavyweights. The problem? They were political and military strategists, not scientists. They were props. They were there to lend credibility, not to provide oversight. The Wall Street Journal reporter who broke the story, John Carreyrou, said it best: "This board took her at her word." She had 99 percent voting control. They couldn't have stopped her even if they'd wanted to. The whole thing was a performance. Holmes faked demos for investors. She forged a report from Pfizer to make it look like they endorsed her tech.
She told partners the U.S. military was using her devices in the field. Lie after lie. Here’s the part that turns my stomach. The moment this stopped being a startup flameout and became something much darker. It's when they went live with Walgreens. This wasn't a demo anymore. This wasn't a pitch deck. They put their fake technology into retail stores to give real medical results to paying customers. They knew the Edison didn't work. They knew they were using hacked Siemens machines in the back room. And they did it anyway. People were making life-and-death decisions based on fraudulent data. One professor, Lester Alexander, said it perfectly: "It was not okay for her to let the device out of the lab." That was the line.
And she sprinted right over it. So what's the lesson here? It's not "don't fly too close to the sun." It's not "manage expectations." It's brutal and it's simple. "Fake it 'til you make it" ends where public safety begins. The moment your product can hurt someone, the game changes. You don't get to be a visionary anymore. You have a responsibility. Holmes didn't fail because her vision was too ambitious. She failed because she chose fraud over failure. Next week, we're going to look at a company that had the opposite problem—a brilliant product that nobody wanted. But for now, just remember this. The market forgives a failed product.
The law does not forgive a con.
Sources for this episode
- Theranos, Inc. | Company, Elizabeth Holmes, Scandal, & Legal Fallout | Britannica
- The Theranos Scandal: A $9 Billion Mirage Exposing Flaws
- The Chronicles of an Evil Genius: Elizabeth Holmes and Theranos
- Patient Advocacy Lies at Heart of FDA Agent’s Theranos Case | FDA
- Theranos' Bad Blood - Ethics Unwrapped
- Lessons from Theranos – Restructuring Biomedical Innovation - PMC
- University of Arkansas, Fayetteville University of Arkansas, Fayetteville
- The rise and fall of Elizabeth Holmes: A timeline | CNN Business
- A Case Study: “Theranos - The White Elephant That Wanted to Be a Unicorn”
- Theranos and the Tale of the Disappearing Board of Directors - Idaho State Bar
- Governance at Theranos (A): A blindsided board - IMD business school for management and leadership courses
- Theranos - Wikipedia
Made with AI. AI may assist this episode’s research, and it writes and voices the episode. Neither the transcript nor this page is an editorial fact check. To report an error, email hi@lissin.com with the episode URL and timestamp. See our editorial standards.
Make your own show like this
Choose a topic you want to hear about, and Lissin makes the show around that choice.
Get Lissin for iPhoneMore to listen to
Tech Bharat Insider
India's Tech Insiders: Jio's Big IPO, AI Moves and the Real Startup Stories
US Tech Buzz Daily
US Tech Wake-Up: Your No-Nonsense Morning Briefing
AI Daily Briefing
AI Moves That Matter: Daily Briefing on Models, Money and Real Breakthroughs
AI Launch Briefs
AI Agents Go to War: Anthropic and OpenAI Shake Up the Enterprise
About Startup Failures Uncovered
Weekly AI-generated case studies of failed startups, the decisions that sank them and the lessons for founders.
